We are live on ! Find out more
IMNM icon

Immunome
IMNM

31 hedge funds and large institutions have $64.7M invested in Immunome in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more capital invested

Capital invested by funds: $19.5M → $64.7M (+$45.2M)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

24% more funds holding

Funds holding: 25 → 31 (+6)

1.2% less ownership

Funds ownership: 19.11% → 17.91% (-1.2%)

33% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 12

Holders
31
Holders Change
+6
Holders Change %
+24%
% of All Funds
0.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
8
Reduced
12
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.83M
2
BlackRock
BlackRock
New York
+$1.02M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$849K
4
State Street
State Street
Massachusetts
+$809K
5
BIM
Baldwin Investment Management
Pennsylvania
+$631K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.83M
2
PCM
Prentice Capital Management
Connecticut
-$2.1M
3
Millennium Management
Millennium Management
New York
-$657K
4
GPCM
Granite Point Capital Management
Massachusetts
-$645K
5
KC
Kepos Capital
New York
-$645K

IMNM Hedge Fund Activity: Q1 2021 in Review

31 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q1 2021, worth a combined $64.7M — up 232% from $19.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IMNM positions and 3 closed out — a net gain of 6 holders — while 8 added to existing stakes and 12 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $3.83M. The largest seller was Fidelity Investments, cutting an estimated $2.83M.

  • 31 institutional investors held Immunome (IMNM) as of Q1 2021, up from 25 in Q4 2020.
  • Funds reported $64.7M of Immunome stock for Q1 2021, up 232% quarter-over-quarter.
  • 9 funds opened new Immunome positions in Q1 2021 and 3 closed out, a net change of +6 holders.
  • The largest Immunome buyer in Q1 2021 was Vanguard Group, an estimated $3.83M added.
  • The largest Immunome seller in Q1 2021 was Fidelity Investments, an estimated $2.83M sold.

Based on aggregated 13F filings for Q1 2021.